Here's why the NIB (ASX:NHF) share price is pushing higher today

Here's what's happening with the NIB share price today…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The NIB Holdings Limited (ASX: NHF) share price is pushing higher on Thursday morning.

In early trade, the private health insurer's shares are up over 1% to $7.02.

An older woman clasps her hands with joy, smiling at the news on her computer as she sits at her kitchen bench..

Image source: Getty Images

Why is the NIB share price pushing higher?

The catalyst for the rise in the NIB share price this morning has been the release of an update on its premium increases for next year.

According to the release, the company has received approval from the Federal Minister for Health to increase health insurance premiums by an average of 2.66%. This is the company's lowest premium change in two decades.

However, just because the premium increase has been approved, doesn't necessarily mean the company will actually increase them immediately on 1 April.

NIB's Managing Director, Mark Fitzgibbon, revealed that the company is considering deferring premium increases in recognition of the ongoing impact of COVID-19 on its members.

He said: "It's possible the increase could be deferred for likely three months depending upon developments, especially in relation to our claims experience and risk equalisation commitment. We'll provide details on what this looks like for our members in the new year."

Nobody likes premium increases but…

And while Mr Fitzgibbon acknowledged that consumers never welcome premium increases, he stressed that they are necessary to keep pace with the rising cost of healthcare treatment.

Mr Fitzgibbon commented: "We've worked hard to keep our price changes to a record low while still allowing us to fund medical treatment for our members when and where they need it. We're also investing more in our members' future health by leveraging data science and technology to deliver more personalised healthcare through unique products, digital health services and health management programs."

The Managing Director also highlighted that the company's average premiums are still lower than average. Following the 2022 premium increase, NIB's annual average premium per single equivalent unit is estimated to be $2,484. This compares to the industry average of $2,657.

Incidentally, this morning Medibank Private Ltd (ASX: MPL) one-upped NIB by announcing that it will defer its premium increases for five months from 1 April. After which, its premiums will increase by an average of 3.1%, which is its lowest increase in 21 years.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Broker Notes

Up 1,250% in a year, why 4DMedical shares can keep charging higher

A top analyst forecasts more outperformance from the surging shares.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused.
Healthcare Shares

Down 31%: Is there any chance of a rebound from ResMed shares?

The ASX healthcare share has lost 31% over the past 12 months.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

If I invested $5,000 in this ASX healthcare stock 12 months ago, I'd have over $67k today!

This ASX healthcare stock is bucking the trend.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Down 35% for the year, is it time to buy this beaten-down ASX biotech?

Stronger revenue numbers signal potential upside.

Read more »